[go: up one dir, main page]

MA41174A - Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta - Google Patents

Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta

Info

Publication number
MA41174A
MA41174A MA041174A MA41174A MA41174A MA 41174 A MA41174 A MA 41174A MA 041174 A MA041174 A MA 041174A MA 41174 A MA41174 A MA 41174A MA 41174 A MA41174 A MA 41174A
Authority
MA
Morocco
Prior art keywords
pi3kbeta
inhibitors
derivatives used
imidazopyridazine derivatives
imidazopyridazine
Prior art date
Application number
MA041174A
Other languages
English (en)
Other versions
MA41174B1 (fr
Inventor
Patrick René Angibaud
Didier Jean-Claude Berthelot
Sophie Coupa
Christophe Gabriel Marcel Demestre
Lieven Meerpoel
Guillaume Jean Maurice Mercey
Laurence Anne Mevellec
Christophe Meyer
Elisabeth Thérèse Jeanne Pasquier
Isabelle Noëlle Constance Pilatte
Virginie Sophie Poncelet
Olivier Alexis Georges Querolle
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA41174A publication Critical patent/MA41174A/fr
Publication of MA41174B1 publication Critical patent/MA41174B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Taps Or Cocks (AREA)
MA41174A 2014-12-19 2015-12-18 Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta MA41174B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199322 2014-12-19
EP15810784.7A EP3233862B1 (fr) 2014-12-19 2015-12-18 Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
PCT/EP2015/080604 WO2016097347A1 (fr) 2014-12-19 2015-12-18 Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pι3κβ

Publications (2)

Publication Number Publication Date
MA41174A true MA41174A (fr) 2017-10-25
MA41174B1 MA41174B1 (fr) 2019-09-30

Family

ID=52134002

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41174A MA41174B1 (fr) 2014-12-19 2015-12-18 Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta

Country Status (26)

Country Link
US (1) US10087187B2 (fr)
EP (1) EP3233862B1 (fr)
JP (1) JP6568588B2 (fr)
KR (1) KR20170095239A (fr)
CN (1) CN107108634B (fr)
AU (1) AU2015366190B2 (fr)
BR (1) BR112017012930A2 (fr)
CA (1) CA2967551A1 (fr)
CY (1) CY1122381T1 (fr)
DK (1) DK3233862T3 (fr)
EA (1) EA029789B1 (fr)
ES (1) ES2761051T3 (fr)
HR (1) HRP20191550T1 (fr)
HU (1) HUE045220T2 (fr)
IL (1) IL252866B (fr)
LT (1) LT3233862T (fr)
MA (1) MA41174B1 (fr)
MD (1) MD3233862T2 (fr)
ME (1) ME03517B (fr)
MX (1) MX2017008074A (fr)
PL (1) PL3233862T3 (fr)
PT (1) PT3233862T (fr)
RS (1) RS59301B1 (fr)
SI (1) SI3233862T1 (fr)
SM (1) SMT201900509T1 (fr)
WO (1) WO2016097347A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018007068B1 (pt) 2015-10-09 2024-01-02 Janssen Pharmaceutica N.V. Derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta, seu uso e composição farmacêutica que os compreende
HUE054118T2 (hu) 2016-06-16 2021-08-30 Janssen Pharmaceutica Nv Biciklusos piridin-, pirazin- és pirimidin-származékok mint PI3K béta-inhibitorok
EA201992296A1 (ru) 2017-03-29 2020-02-12 Янссен Фармацевтика Нв Производные хиноксалина и пиридопиразина в качестве ингибиторов pi3k-бета
CN113454086B (zh) 2019-02-07 2025-03-14 百济神州有限公司 作为tlr7激动剂的咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物
CN110128505A (zh) * 2019-05-21 2019-08-16 梯尔希（南京）药物研发有限公司 一种戈舍瑞林杂质的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US20090215818A1 (en) 2006-07-24 2009-08-27 Smithkline Beecham Corporation Thiozolidinedione derivatives as pi3 kinase inhibitors
US20110021513A1 (en) 2006-09-07 2011-01-27 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
PE20090215A1 (es) * 2007-05-09 2009-03-30 Novartis Ag Compuestos derivados de imidazopiridazinas como inhibidores de cinasa
WO2009060197A1 (fr) 2007-11-08 2009-05-14 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyridazines utilisées comme qu'inhibiteurs de protéine kinases
AR070487A1 (es) * 2008-02-28 2010-04-07 Novartis Ag Derivados de 3- metil- imidazo -( 1,2-b)- piridazina
WO2010007099A1 (fr) * 2008-07-15 2010-01-21 Cellzome Limited Dérivés de 2-aminoimidazo[1,2-b]pyridazine en tant qu’inhibiteurs de pi3k
HRP20190016T1 (hr) 2009-08-17 2019-03-08 Intellikine, Llc Heterociklički spojevi i njihova upotreba
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011058109A1 (fr) 2009-11-12 2011-05-19 Ucb Pharma S.A. Dérivés de pyrrole et d'imidazole bicycliques condensés en tant qu'inhibiteurs de kinase
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
PE20140192A1 (es) * 2010-10-06 2014-02-24 Glaxosmithkline Llc Derivados de bencimidazol como inhibidores de cinasa pi3
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
WO2013028263A1 (fr) 2011-08-24 2013-02-28 Glaxosmithkline Llc Dérivés pyrazolopyrimidines en tant qu'inhibiteurs de pi3 kinase
US8778937B2 (en) 2011-12-20 2014-07-15 Glaxosmithkline Llc Benzimidazole boronic acid derivatives as PI3 kinase inhibitors
US8906910B2 (en) 2011-12-20 2014-12-09 Glaxosmithkline Llc Imidazopyridine derivatives as PI3 kinase
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents

Also Published As

Publication number Publication date
LT3233862T (lt) 2019-09-10
EA029789B1 (ru) 2018-05-31
EA201791396A1 (ru) 2017-10-31
RS59301B1 (sr) 2019-10-31
SMT201900509T1 (it) 2019-11-13
JP2017538734A (ja) 2017-12-28
IL252866B (en) 2020-09-30
AU2015366190B2 (en) 2020-01-23
BR112017012930A2 (pt) 2018-01-09
CN107108634A (zh) 2017-08-29
IL252866A0 (en) 2017-08-31
EP3233862A1 (fr) 2017-10-25
ME03517B (fr) 2020-04-20
CN107108634B (zh) 2020-09-15
PT3233862T (pt) 2019-10-09
MD3233862T2 (ro) 2019-11-30
US20180002336A1 (en) 2018-01-04
CA2967551A1 (fr) 2016-06-23
WO2016097347A1 (fr) 2016-06-23
HUE045220T2 (hu) 2019-12-30
MA41174B1 (fr) 2019-09-30
US10087187B2 (en) 2018-10-02
JP6568588B2 (ja) 2019-08-28
SI3233862T1 (sl) 2019-09-30
HRP20191550T1 (hr) 2019-11-29
DK3233862T3 (da) 2019-10-07
CY1122381T1 (el) 2021-01-27
ES2761051T3 (es) 2020-05-18
PL3233862T3 (pl) 2020-01-31
MX2017008074A (es) 2018-01-09
KR20170095239A (ko) 2017-08-22
EP3233862B1 (fr) 2019-07-03
AU2015366190A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
IL287331A (en) Use of 3-isoxazolidinones compounds as selective herbicides
IL282167A (en) Metabolized carbonucleosides and their use for cancer treatment
EP3596075C0 (fr) Azaindoles utilisés en tant qu'inhibiteurs de hpk1
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
EP3386981A4 (fr) Hétérocycles utiles en tant qu'agents anticancereux
HUE054672T2 (hu) TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
EP3457851A4 (fr) Dérivés de sobétirome
SI4119569T1 (sl) Konjugirane protismiselne spojine za uporabo v terapiji
EP3328840A4 (fr) Composés bicycliques triazolo substitués en tant qu'inhibiteurs de pde2